Anaconda Biomed Appoints Trent Reutiman as New CEO to Drive U.S. Expansion
Portfolio - People | Jan 07, 2025 | Ysios Capital
Anaconda Biomed S.L., a medical technology innovator focusing on next-generation thrombectomy systems for ischemic stroke, has appointed Trent Reutiman as its new CEO. With his vast experience in vascular technologies and prior leadership roles at Mercator MedSystems and IDEV, Reutiman is tasked with leading Anaconda's expansion into the U.S. market. He will work towards securing FDA approval for the ANA5 Advanced Neurovascular Access (ANA Funnel Catheter Technology), designed to improve neurovascular interventions. Reutiman takes over from Francois Salmon, who transitions to Board Chairman. Under Salmon’s guidance, the company has made strides with its ANA Funnel Catheter, which offers significant potential in mechanical thrombectomy procedures. Anaconda Biomed, backed by prominent life science investment firms and public grants, is focused on delivering meaningful improvement in ischemic stroke patient outcomes through its innovative technologies.
Sectors
- Medical Technology
- Life Sciences Investment
Geography
- United States – The U.S. is a significant market for Anaconda Biomed's expansion efforts under its new CEO, Trent Reutiman, who will establish a presence there.
- Spain – Anaconda Biomed is based in Barcelona, Spain, which serves as its operational and developmental hub.
Industry
- Medical Technology – Anaconda Biomed operates in the medical technology sector, focusing on developing thrombectomy systems for ischemic stroke treatment.
- Life Sciences Investment – The involvement of investment firms such as Ysios Capital and others indicates the life sciences investment sector's interest in Anaconda Biomed's innovative medical solutions.
Financials
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Anaconda Biomed S.L. | Target Company | Company | A medical technology company that develops thrombectomy systems for ischemic stroke treatment. |
| Ysios Capital | Private Equity Firm | Company | A life sciences investment firm backing Anaconda Biomed. |
| Trent Reutiman | New CEO | Person | A seasoned medtech executive appointed as CEO of Anaconda Biomed to lead its U.S. expansion. |
| Francois Salmon | Board Chairman | Person | Previous CEO of Anaconda Biomed who will now serve as Board Chairman. |
| Mercator MedSystems Inc. | Previous Employer of CEO | Company | A company where Trent Reutiman was CEO, focusing on catheter-based drug delivery systems. |
| Shenzhen Salubris Pharmaceuticals Co. | Strategic Partner | Company | A China-based pharmaceutical company partnered with Mercator MedSystems under Reutiman's leadership. |